Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma

Immune landscape of adenoid cystic carcinoma: reversible downregulation of HLA class I

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma